Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)
Completed
Gilead Sciences
Phase 1/Phase 2
2009-11-01
This study seeks to (i) determine a safe and tolerated dose of CYT387 (momelotinib) given to
patients with PMF, post-PV or post-ET and, (ii) assess the effectiveness of
orally-administered CYT387 as a treatment for PMF, post-PV or post-ET.
Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)
Completed
Sierra Oncology, Inc.
Phase 1/Phase 2
2009-11-01
This study seeks to (i) determine a safe and tolerated dose of CYT387 (momelotinib) given to
patients with PMF, post-PV or post-ET and, (ii) assess the effectiveness of
orally-administered CYT387 as a treatment for PMF, post-PV or post-ET.
Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)
Completed
Gilead Sciences
Phase 2
2010-11-01
This extension protocol to the core study CCL09101 allows patients who have tolerated the
drug and derived a clinical benefit, to continue to receive treatment beyond the 9 cycles of
the core protocol. Long term safety and efficacy of CYT387 (momelotinib) will be evaluated.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
